Saxo Bank, the online trading and investment specialist, today releases their Q3 outlook that views Europe as insolvent, in a phase of denial of the actual problems and without a credible path forward. The Bank’s analysts also predict that growth in China will decrease to 6.5 percent, marking the next quarter as the low point for China and for world growth in general.
For the current crisis, Saxo Bank operates with a three-phase model that includes; Denial (which prompts policy-makers and central bankers to rely on quantitative easing and financial stimulus); Protest (where the public votes new governments which still fail to address the real problems) and; Mandate for Change (which forces policy-makers to take real action). According to the Bank, the EU has remained embedded in the first and second phases, having yet to arrive at a mandate for change.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/saxobank/56575/
Sands China’s Cotai Strip® development was beautifully aflame in celebration Thursday evening, as the integrated resort city introduced to Macao the latest additions at Sands® Cotai Central, led by the launch of Sheraton Macao Hotel, Cotai Central, which has the double distinction of being the largest hotel for both Macao and Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58010-sands-cotai-central-celebrates-second-phase-opening
Unveiling several transformational changes to reach new guests, Olive Garden announced its first new national advertising campaign in nearly 10 years and the initial phase of significant menu innovations that include lighter Italian entrées, new Porta Vita signature wines and a unique “Dinner Today & Dinner TomorrowSM” limited-time offer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57988-olive-garden-unveils-transformational-changes
Nespresso, the worldwide reference for highest-quality portioned premium coffee, announced today the launch of the second phase of its television advertising campaign “The best café. Yours.” The U.S. and Canada campaign further increases brand awareness among coffee lovers amidst the recent growth of the single serve coffee market. Nespresso has enlisted Oscar-winning actress and coffee lover Penelope Cruz to star in the 30-second television spot as she epitomizes the sophistication, elegance and passion of the brand.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59154-nespresso-what-else-penelope-cruz
Two beautiful baby girls had their public debut today at The Children’s Hospital of Philadelphia: Allison June and Amelia Lee Tucker, formerly conjoined twins, separated at the Hospital on Nov. 7. The Hospital held a press conference this morning to highlight this new phase in the lives of both infants.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59552-children-s-hospital-of-philadelphia-tucker-conjoined-twins-separated
Volkswagen startet 30 Jahre nach seinem Markteintritt in China in eine Phase nachhaltigen Wachstums. Im Zuge des Ausbaus der Fertigungskapazitäten investieren die beiden chinesischen Joint-Ventures des Volkswagen Konzerns bis 2015 mehr als zwei Drittel von insgesamt 9,8 Milliarden Euro in hocheffiziente Produkte. Der für China zuständige Vorstand der Volkswagen Aktiengesellschaft Prof. Dr. Jochem Heizmann, präzisierte am Vortag der Auto Shanghai 2013 die auf den chinesischen Markt zugeschnittene Elektromobilitäts-Strategie. Es sei geplant, von 2014/2015 an Fahrzeuge mit elektrifiziertem Antrieb anzubieten, die zum Teil lokal produziert werden. Bereits 26 Modelle des Konzerns sind von staatlicher Seite als besonders energiesparend und umweltschonend anerkannt worden. Volkswagen habe den verbrauch seiner in China derzeit mehr als 70 Modelle umfassenden Flotte zwischen 2005 und 2010 um 20 Prozent reduziert und werde ihn bis 2015 um weitere 11 Prozent senken.
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
New entertainment integrations and social media initiatives move the “ugly truth” campaign into a new phase this month, further seeding important tobacco-related facts and messages with teens and young adults. The latest advertising campaign from truth – the nation’s largest youth smoking prevention campaign – features its first television ads since 2010, and a host of marketing and digital tools to educate and connect with teens and young people through a range of digital media initiatives and entertainment integrations.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62254-truth-campaign-gets-uglier-entertainment-integrations-expand-conversation
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
Online Registration Guidline
ACRI is specialized in providing Clinical Research Courses like Pg Diploma in clinical CDM and SAS course with guarantee internship in leading CRO’S & 100% Placement.
Reach us at:
Avigna Clinical Research Institute:-
No.33,3rd Floor,15th Cross,
2nd Phase,J.P.Nagar,100ft Ring Road,
Bangalore-560078
080-26588910 / 91-9741600499
http://www.acriindia.com
info@acriindia.com
Today Concentrix Corporation, a wholly-owned subsidiary of SYNNEX Corporation (NYSE: SNX), announced the addition of 19 delivery locations, across 13 countries, completing the second phase of the acquisition of IBM's global customer care and industry process services business. With over 95% of the acquisition completed, Concentrix continues to advance its position as a leader in the customer care and industry process services market, with over 45,000 employees delivering high value services.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7146451-concentrix-completes-2nd-phase-of-ibm-customer-care-business-acquisition
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
